Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Kura Oncology (KURA) Non Operating Income (2023 - 2026)

Kura Oncology has reported Non Operating Income over the past 4 years, most recently at $5.5 million for Q1 2026.

  • Quarterly Non Operating Income fell 26.77% to $5.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $23.7 million through Mar 2026, changed 0.32% year-over-year, with the annual reading at $25.3 million for FY2025, 18.99% up from the prior year.
  • Non Operating Income was $5.5 million for Q1 2026 at Kura Oncology, down from $7.5 million in the prior quarter.
  • Over five years, Non Operating Income peaked at $7.5 million in Q1 2025 and troughed at $2.5 million in Q1 2023.
  • The 4-year median for Non Operating Income is $5.1 million (2024), against an average of $4.7 million.
  • Year-over-year, Non Operating Income skyrocketed 97.32% in 2024 and then decreased 26.77% in 2026.
  • A 4-year view of Non Operating Income shows it stood at $4.0 million in 2023, then skyrocketed by 32.19% to $5.3 million in 2024, then soared by 42.64% to $7.5 million in 2025, then decreased by 26.77% to $5.5 million in 2026.
  • Per Business Quant, the three most recent readings for KURA's Non Operating Income are $5.5 million (Q1 2026), $7.5 million (Q1 2025), and $5.3 million (Q4 2024).